ALEC
NASDAQAlector Inc.
Price$1.63-0.52 (-24.36%)
2026-03-042026-06-05
News · 26 weeks34-56%
2025-12-142026-06-07
Mix2190d
- Insider8(38%)
- SEC Filings7(33%)
- Other4(19%)
- Analyst2(10%)
Latest news
25 items- INSIDERDirector Scheller Richard H was granted 10,833 shares, increasing direct ownership by 11% to 106,199 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERChief Executive Officer Rosenthal Arnon sold $172,191 worth of shares (87,216 units at $1.97), decreasing direct ownership by 4% to 2,367,206 units (SEC Form 4) to cover withholding tax4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERPrincipal Accounting Officer Wong-Sarad Grace sold $17,813 worth of shares (9,184 units at $1.94) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,461 units (SEC Form 4) to satisfy tax liability4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERCFO & Chief Business Officer Berkley Neil Lindsay sold $38,221 worth of shares (19,360 units at $1.97), decreasing direct ownership by 5% to 379,900 units (SEC Form 4) to cover taxes4 - Alector, Inc. (0001653087) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.SCHEDULE 13G/A - Alector, Inc. (0001653087) (Subject)
- SECSEC Form 8-K filed by Alector Inc.8-K - Alector, Inc. (0001653087) (Filer)
- SECSEC Form 424B5 filed by Alector Inc.424B5 - Alector, Inc. (0001653087) (Filer)
- SECSEC Form 10-Q filed by Alector Inc.10-Q - Alector, Inc. (0001653087) (Filer)
- SECAlector Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Alector, Inc. (0001653087) (Filer)
- PRAlector Reports First Quarter 2026 Financial Results and Provides Business UpdateAdvancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) $206.5 million in cash, cash equivalents and investments provide runway at least through 2027 SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devasting progression of neurodegeneration, today report
- PRAlector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer's disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson's disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs— SOUTH SAN FRANCISCO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodege
- SECSEC Form DEFA14A filed by Alector Inc.DEFA14A - Alector, Inc. (0001653087) (Filer)
- SECSEC Form DEF 14A filed by Alector Inc.DEF 14A - Alector, Inc. (0001653087) (Filer)
- INSIDERSEC Form 4 filed by Wong-Sarad Grace4 - Alector, Inc. (0001653087) (Issuer)
- ANALYSTAlector upgraded by Cantor FitzgeraldCantor Fitzgerald upgraded Alector from Neutral to Overweight
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alector Inc.SCHEDULE 13G/A - Alector, Inc. (0001653087) (Subject)
- INSIDERChief Executive Officer Rosenthal Arnon was granted 116,246 shares, increasing direct ownership by 5% to 2,454,422 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERCFO & Chief Business Officer Berkley Neil Lindsay was granted 54,600 shares, increasing direct ownership by 16% to 399,260 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERPrincipal Accounting Officer Wong-Sarad Grace sold $2,650 worth of shares (1,000 units at $2.65), decreasing direct ownership by 0.93% to 106,465 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- SECSEC Form S-3 filed by Alector Inc.S-3 - Alector, Inc. (0001653087) (Filer)
- ANALYSTAlector upgraded by BTIG Research with a new price targetBTIG Research upgraded Alector from Neutral to Buy and set a new price target of $6.00
- INSIDERPrincipal Accounting Officer Wong-Sarad Grace sold $7,012 worth of shares (3,367 units at $2.08), decreasing direct ownership by 3% to 107,465 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERPrincipal Accounting Officer Wong-Sarad Grace sold $17,138 worth of shares (8,071 units at $2.12), decreasing direct ownership by 7% to 110,832 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERChief Executive Officer Rosenthal Arnon sold $173,822 worth of shares (81,864 units at $2.12), decreasing direct ownership by 3% to 2,338,176 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
- INSIDERCFO & Chief Business Officer Berkley Neil Lindsay sold $62,954 worth of shares (29,649 units at $2.12), decreasing direct ownership by 8% to 344,660 units (SEC Form 4)4 - Alector, Inc. (0001653087) (Issuer)
ALEC FAQ
7 questionsWhat does Alector Inc. do?
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment...Where does ALEC stock trade?
Alector Inc. (ALEC) is listed on NASDAQ.What sector and industry is ALEC in?
Alector Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Alector Inc. go public?
Alector Inc. (ALEC) completed its IPO in 2019.What are analysts saying about ALEC?
Alector Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-04-15. Recent price targets range from $150.00 to $600.00.What companies are similar to ALEC?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ALEC side-by-side with any of them on Quantisnow.How can I track ALEC on Quantisnow?
Quantisnow aggregates Alector Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALEC to receive live email and push alerts on every new disclosure.